Naoki Kumashiro

List of Publications by Year
in descending order

23 papers	1,740 citations	516561 16 h-index	642610 23 g-index
23 all docs	23 docs citations	23 times ranked	3408 citing authors

#	Article	IF	Citations
1	A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovascular Diabetology, 2021, 20, 32.	2.7	34
2	Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with wellâ€controlled typeÂ2 diabetes: A 24â€week randomized controlled trial. Journal of Diabetes Investigation, 2021, 12, 1816-1826.	1.1	7
3	Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovascular Diabetology, 2020, 19, 1.	2.7	121
4	Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia. Diabetes Research and Clinical Practice, 2020, 169, 108412.	1.1	9
5	Whole hepatic lipid volume quantification and color mapping by multiâ€slice and multiâ€point magnetic resonance imaging. Hepatology Research, 2019, 49, 1374-1385.	1.8	4
6	Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozinâ€™s Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes. Diabetes Therapy, 2019, 10, 1509-1521.	1.2	2
7	Efficacy of intermittent empagliflozin supplementation on dietary selfâ€management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24â€week randomized controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 303-311.	2.2	3
8	Mechanisms of sleep deprivation-induced hepatic steatosis and insulin resistance in mice. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E848-E858.	1.8	28
9	Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study. Cardiovascular Diabetology, 2018, 17, 86.	2.7	2
10	Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial. Diabetes Therapy, 2017, 8, 783-792.	1.2	28
11	Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function. Journal of Diabetes Investigation, 2017, 8, 330-340.	1.1	33
12	Characteristics of hepatic insulinâ€sensitive nonalcoholic fatty liver disease. Hepatology Communications, 2017, 1, 634-647.	2.0	16
13	Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovascular Diabetology, 2017, 16, 84.	2.7	177
14	Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1143-1148.	3.3	176
15	Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nature Medicine, 2014, 20, 759-763.	15.2	178
16	Targeting Pyruvate Carboxylase Reduces Gluconeogenesis and Adiposity and Improves Insulin Resistance. Diabetes, 2013, 62, 2183-2194.	0.3	107
17	Role of patatinâ€like phospholipase domainâ€containing 3 on lipidâ€induced hepatic steatosis and insulin resistance in rats. Hepatology, 2013, 57, 1763-1772.	3.6	72
18	Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16381-16385.	3.3	475

#	Article	IF	Citations
19	Determinants of intramyocellular lipid accumulation after dietary fat loading in non-obese men. Journal of Diabetes Investigation, 2011, 2, 310-317.	1.1	32
20	Impact of Oxidative Stress and Peroxisome Proliferatorâ€“Activated Receptor Î³ Coactivator-1Î± in Hepatic Insulin Resistance. Diabetes, 2008, 57, 2083-2091.	0.3	87
21	Effects of Diet-Induced Moderate Weight Reduction on Intrahepatic and Intramyocellular Triglycerides and Glucose Metabolism in Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3326-3329.	1.8	113
22	Long-term Effect of Combination Therapy with Mitiglinide and Once Daily Insulin Glargine in Patients who were Successfully Switched from Intensive Insulin Therapy in Short-term Study. Endocrine Journal, 2007, 54, 163-166.	0.7	14
23	Therapeutic Efficacy of Mitiglinide Combined with Once Daily Insulin Glargine after Switching from Multiple Daily Insulin Regimen of Aspart Insulin and Glargine in Patients with Type 2 Diabetes Mellitus. Endocrine Journal, 2006, 53, 67-72.	0.7	22